Cervical cancer primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(12 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cervical cancer}}
{{Cervical cancer}}
{{CMG}}
{{CMG}}{{AE}}{{Nnasiri}}


==Overview==
==Overview==
Prevention of cervical cancer includes a comprehensive approach involving awareness, screening, and usage of preventative vaccinations.
Most effective and cost efficient [[primary prevention]] available for cervical cancer is [[vaccination]] against high risk strains of [[human papilloma virus]], which are [[HPV]] 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.  


==Primary Prevention==
==Primary Prevention==
 
:[[Primary prevention]] method for cervical cancer is vaccination against [[HPV]] types 16 and 18, there are two type of [[FDA]] approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to [[CDC]] recommendation. <ref name="MarkowitzUnger2009">{{cite journal|last1=Markowitz|first1=L. E.|last2=Unger|first2=E. R.|last3=Saraiya|first3=M.|title=Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges|journal=JNCI Journal of the National Cancer Institute|volume=101|issue=7|year=2009|pages=439–440|issn=0027-8874|doi=10.1093/jnci/djp044}}</ref>
'''Avoid being exposed to HPV'''
:*[[HPV]] vaccine also is recommended for following target population:
:*Having sex at an early age
:**Young homosexual or bisexual men who have sex with men through age 26
:*Having many sexual partners
:**[[HIV]] infected young adult who have weakened immune system through age 26
:*Having a partner who has had many sex partners
:**Young adults who are transgender through age 26
:*Having sex with uncircumcised males
:
 
:*The trade name of the available [[FDA]] approved vaccines include: <ref name="pmid19895230">{{cite journal |vauthors=Grce M |title=Primary and secondary prevention of cervical cancer |journal=Expert Rev. Mol. Diagn. |volume=9 |issue=8 |pages=851–7 |date=November 2009 |pmid=19895230 |doi=10.1586/erm.09.64 |url=}}</ref>
'''Delay sex''': Waiting to have sex until you are older can help you avoid HPV.
:**[[Gardasil]], quadrivalent [[vaccine]], composed of [[HPV]] 6, 11, 16 and 18.  
 
:**[[Cervarix]], bivalent [[vaccine]], composed of [[HPV]] 16 and 18.  
'''Use condoms:''' Condoms provide some protection against HPV.
 
'''Avoidance of smoking:'''Clinical survey show no smoking is another important way to reduce the risk of cervical precancer and cancer.
 
'''Get vaccinated:''' Vaccines have been developed that can protect women from HPV infections.
 
'''Regular gynecological examinations'''
:*[[Pap test]]
:*Treatment of precancerous abnormalities
 
===Awareness===
According to the US [[National Cancer Institute]]'s 2005 Health Information National Trends survey, only 40% of American women surveyed had heard of human papillomavirus (HPV) infection and only 20% had heard of its link to cervical cancer.<ref>{{cite web|url =http://www.msnbc.msn.com/id/15713966/|title=Most women unaware about HPV (MSNBC)}}</ref> In 2006 an estimated 10,000 women in the US will be diagnosed with this type of cancer and nearly 4,000 will die from it.<ref>[http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_cervical_cancer_8.asp?sitearea=]</ref>
 
===Screening===
The widespread introduction of the [[pap smear|Papanicolaou test]], or ''pap smear'' for cervical cancer screening has been credited with dramatically reducing the incidence and mortality of cervical cancer in developed countries.<ref>[http://www.aafp.org/afp/20000301/1369.html]</ref> The pap smear suggests the presence of [[cervical intraepithelial neoplasia]] (premalignant changes in the cervix) before a cancer has developed, allowing for further workup. Recommendations for how often a Pap smear should be done vary from once a year to once every five years. The [[American Cancer Society]] recommends that cervical cancer screening should begin approximately three years after the onset of vaginal intercourse and/or no later than twenty-one years of age.<ref>{{cite journal |author=Saslow D, Runowicz CD, Solomon D, ''et al'' |title=American Cancer Society guideline for the early detection of cervical neoplasia and cancer |journal=CA: a cancer journal for clinicians |volume=52 |issue=6 |pages=342-62 |year=2002 |pmid=12469763 |doi=}}</ref> If premalignant disease or cervical cancer is detected early, it can be treated relatively noninvasively, and without impairing fertility.
 
The [[HPV test]] is a newer technique for cervical cancer screening which detects the presence of [[human papillomavirus]] infection in the cervix. It is more [[sensitivity (tests)|sensitive]] than the pap smear (less likely to produce false negative results), but less specific (more likely to produce false positive results) and its role in routine screening is still evolving.  Since more than 99% of invasive cervical cancers worldwide contain HPV, some researchers recommend that HPV testing be done together with routine cervical screening (Walboomers ''et al'', 1999). But, given the prevalence of HPV (around 80% infection history among the sexually active population) others suggest that routine HPV testing would cause undue alarm to carriers.
 
===Vaccination===
{{main|HPV vaccine}}
 
[[Merck & Co.]] has developed a vaccine against four strains of HPV (6,11,16,18), called [[Gardasil]]™. It is now on the market after receiving approval from the US Food and Drug Administration on June 8, 2006.<ref>[http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html]</ref> Gardasil is targeted at girls and women of age 9 to 26 because the vaccine only works if given before infection occurs; therefore, public health workers are targeting girls before they begin having sex. The use of the vaccine in men to prevent genital warts and interrupt transmission to women is initially considered only a secondary market. The high cost of this vaccine has been a cause for concern. Gardasil has also been approved in the EU.<ref>BBC [http://news.bbc.co.uk/1/hi/health/5370504.stm EU approves cervical cancer jab] 22 September 2006</ref>
 
[[GlaxoSmithKline]] has developed a vaccine called [[Cervarix]]™ which has been shown to be 100% effective in preventing HPV strains 16 and 18 and is 100% effective for more than four years.<ref>[http://www.medicalnewstoday.com/medicalnews.php?newsid=38317]</ref>
These strains together cause about 70% of cervical cancer cases. Cervarix should be approved by year's end.<ref>The Grand Rapids Press [http://www.mlive.com/news/grpress/index.ssf?/base/news-31/1155818704291630.xml&coll=6 About the cervical cancer vaccine] 17 August 2006</ref><ref>BBC [http://news.bbc.co.uk/1/hi/health/5311598.stm Cancer jab 'stops 75% of deaths'] 4 September 2006</ref>
 
Neither Merck & Co. nor GlaxoSmithKline invented the vaccine. The vaccine's key developmental steps are claimed by the [[National Cancer Institute]] in the US, the University of Rochester in New York, Georgetown University in Washington, DC, and the Queensland University in Brisbane, Australia. Both Merck & Co. and GlaxoSmithKline have licensed patents from all of these parties.<ref>[http://jnci.oxfordjournals.org/cgi/content/full/98/7/433]</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}


[[Category:Disease]]
[[Category:Disease]]
[[Category:Gynecology]]
[[Category:Gynecology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:primary care]]
[[Category:Medicine]]
{{WH}}
{{WS}}

Latest revision as of 20:51, 29 July 2020

Cervical cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cervical Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cervical Cancer During Pregnancy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cervical cancer primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cervical cancer primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cervical cancer primary prevention

CDC on Cervical cancer primary prevention

Cervical cancer primary prevention in the news

Blogs on Cervical cancer primary prevention

Directions to Hospitals Treating Cervical cancer

Risk calculators and risk factors for Cervical cancer primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.

Primary Prevention

Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. [1]
  • HPV vaccine also is recommended for following target population:
    • Young homosexual or bisexual men who have sex with men through age 26
    • HIV infected young adult who have weakened immune system through age 26
    • Young adults who are transgender through age 26

References

  1. ↑ Markowitz, L. E.; Unger, E. R.; Saraiya, M. (2009). "Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges". JNCI Journal of the National Cancer Institute. 101 (7): 439–440. doi:10.1093/jnci/djp044. ISSN 0027-8874.
  2. ↑ Grce M (November 2009). "Primary and secondary prevention of cervical cancer". Expert Rev. Mol. Diagn. 9 (8): 851–7. doi:10.1586/erm.09.64. PMID 19895230.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Cervical_cancer_primary_prevention&oldid=1635833"